跳至主要内容
临床试验/NL-OMON35680
NL-OMON35680已完成不适用

Anti TNF therapy and susceptibility for Coxiella burnetii infection - Anti TNF therapy and susceptibility for Coxiella burnetii infection

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 800 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Diagnosis of either rheumatoid arthritis (RA), arthritis psoriatica or bechterew disease
  • Residence in Q fever endemic area (defined by the Institute for Public Health and Environment (RIVM) as *core area*), as determined by the postal code of their home address.
  • Signed written informed consent ;For patients on anti-TNF therapy:
  • Treatment with TNFa blockers either infliximab, etanercept or adalimumab in an adequate dose according to the guidelines
  • Treatment with TNFa blockers is started before 01-01-2011 ;For patients not receiving anti-TNF therapy:
  • Treatment with DMARDs
  • No history of treatment with TNFa blockers

排除标准

  • Age under 18 years
  • Pregnancy or lactation
  • Lymphoma, lymphoproliferative syndromes and other hematologic malignancies
  • Chronic infections, including HIV, hepatitis B or C, mycobacterial disease

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验